NAD+ and Cellular Aging: What the Longevity Research Shows

NAD+ has become one of the most marketed names in longevity, sold as pills, powders, and intravenous infusions. The underlying biology is real and important, but the gap between that biology and what supplementation has been shown to do is wide. This article separates the two: what NAD+ is and why it matters for aging, versus what the human evidence actually demonstrates.

What NAD+ Is

NAD+ stands for nicotinamide adenine dinucleotide. It is not a peptide but a coenzyme, a small helper molecule that many enzymes require to function. It is present in every cell, and life is not possible without it.

NAD+ has two broad jobs. The first is in energy metabolism, where it acts as an electron carrier. Core processes such as glycolysis and the reactions inside mitochondria depend on NAD+ cycling between its oxidized form (NAD+) and its reduced form (NADH) to shuttle electrons. The second job is as a consumable substrate: certain enzymes do not just borrow NAD+, they use it up. These include the sirtuins and the PARP family, discussed below. Because some enzymes consume it, the cell must continually resynthesize NAD+.

Why NAD+ Matters for Aging

The age-related decline

The central observation driving longevity interest is that NAD+ levels decline with age across many tissues and species. This decline correlates with several recognized hallmarks of aging, including mitochondrial dysfunction and genomic instability. The hypothesis that follows is straightforward: if falling NAD+ contributes to age-related decline, then restoring it might slow some aspects of that decline. The hypothesis is reasonable. Whether it holds in practice is the open question.

Sirtuins and DNA repair

Two groups of NAD+-consuming enzymes explain much of the aging connection. Sirtuins are enzymes involved in regulating gene expression, metabolism, and stress responses, and they require NAD+ to work. PARP enzymes participate in DNA repair and also consume NAD+. The idea is that when NAD+ is abundant, these protective systems function well, and when it is scarce, they are constrained. This gives a mechanistic story linking NAD+ to maintenance of the genome and of metabolic health, themes it shares with other longevity-research compounds such as MOTS-c and epithalon.

NAD+ Versus Its Precursors

An important practical point is that most research and most products do not deliver NAD+ directly in a form that easily reaches the inside of cells. NAD+ is a relatively large, charged molecule and does not readily cross cell membranes. Instead, the body builds NAD+ from smaller precursors, and supplementation research has focused on those precursors: nicotinamide mononucleotide (NMN), nicotinamide riboside (NR), and the older forms of vitamin B3. Intravenous NAD+ is also marketed, though how much of an infusion is used as intact NAD+ versus broken down first is debated. The regulatory status of NMN in particular has been contested, with questions raised in the United States about whether it qualifies as a dietary supplement.

What Human Trials Have Found

More than a dozen human clinical trials have administered NAD+ precursors at various doses for periods of up to around six months. The consistent findings are two. First, these precursors have a generally good safety profile at the doses studied. Second, they reliably raise measurable NAD+ levels in blood and some tissues. In other words, the supplements do what they claim biochemically: they increase NAD+.

What the Evidence Does Not Yet Show

The harder question is whether raising NAD+ produces meaningful health or longevity benefits, and here the evidence is limited. Trials have shown some signals in areas such as metabolic measures, but the overall evidence that NAD+ precursors slow aging or prevent age-related disease in otherwise healthy people is weak. Researchers studying the field are explicit that human studies are still at an early stage and that benefits for the average person are not established. A 2026 review examined NAD+ in the context of neurodegenerative disease and aging and consolidated current knowledge, but consolidation is not the same as proof of benefit.

This article is for educational and informational purposes only. It is not intended as medical advice and should not be used to diagnose, treat, or prevent any condition. Always consult with a qualified healthcare professional before making health-related decisions. Clinical trial data referenced here is sourced from peer-reviewed publications and may not reflect the most current findings.